239 related articles for article (PubMed ID: 38130408)
1. Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications.
Assis AJB; Santana BLO; Gualberto ACM; Pittella-Silva F
Front Pharmacol; 2023; 14():1322937. PubMed ID: 38130408
[TBL] [Abstract][Full Text] [Related]
2. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-based precision medicine for hematologic disorders: Advancements, challenges, and prospects.
Sahu S; Poplawska M; Lim SH; Dutta D
Life Sci; 2023 Nov; 333():122165. PubMed ID: 37832631
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
6. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics.
Ghosh D; Venkataramani P; Nandi S; Bhattacharjee S
Cancer Cell Int; 2019; 19():12. PubMed ID: 30636933
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges.
Yi L; Li J
Biochim Biophys Acta; 2016 Dec; 1866(2):197-207. PubMed ID: 27641687
[TBL] [Abstract][Full Text] [Related]
11. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
[TBL] [Abstract][Full Text] [Related]
12. Targeted genome editing in acute lymphoblastic leukemia: a review.
Montaño A; Forero-Castro M; Hernández-Rivas JM; García-Tuñón I; Benito R
BMC Biotechnol; 2018 Jul; 18(1):45. PubMed ID: 30016959
[TBL] [Abstract][Full Text] [Related]
13. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
Quazi S
Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
[TBL] [Abstract][Full Text] [Related]
16. Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
Mehravar M; Roshandel E; Salimi M; Chegeni R; Gholizadeh M; Mohammadi MH; Hajifathali A
Immunol Lett; 2020 Oct; 226():71-82. PubMed ID: 32687855
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
Ou X; Ma Q; Yin W; Ma X; He Z
Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.
Tiwari PK; Ko TH; Dubey R; Chouhan M; Tsai LW; Singh HN; Chaubey KK; Dayal D; Chiang CW; Kumar S
Front Mol Biosci; 2023; 10():1214489. PubMed ID: 37469704
[TBL] [Abstract][Full Text] [Related]
20. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]